A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients

Amit Anand, Lubna Bukhari, Shirley A. Jennings, Cynthia Lee, Mamata Kamat, Anantha Shekhar, John I. Nurnberger, Jeffrey Lightfoot

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objective: The purpose of this study was to investigate the effectiveness of zonisamide in the treatment of bipolar depression. Method: Ten patients with DSM-IV bipolar disorder, depressed phase, who had either not tolerated or not responded to previous treatments were given zonisamide in this add-on open-label study. Zonisamide treatment was started at 100 mg/day and increased by 100 mg every 2 weeks to a maximum of 300 mg/day in divided doses (b.i.d. or t.i.d.). Subjects underwent weekly visits at which they were administered the 17-item Hamilton Rating Scale for Depression (HAM-D), Young Mania Rating Scale (YMRS), and Clinical Global Impressions scale (CGI). Every 2 weeks, subjects also underwent laboratory tests, a urine examination, and a verbal memory test. Outcome measures were analyzed with repeated-measures analysis of variance. Results: Eight subjects completed all 8 weeks of the study. Two subjects completed more than 4 weeks of the study, and their data were analyzed using the last observation carried forward. Bipolar depression subjects had a significant reduction in HAM-D scores (p < .001) and in CGI-Improvement (CGI-I) scores (p < .001). Five of 8 subjects who completed all 8 weeks of the study had more than a 50% decrease in HAM-D scores and were rated much improved on the CGI-I at the end of 8 weeks of treatment. There was no significant drug effect on YMRS scores, weight, or verbal memory. Conclusion: Zonisamide may be a useful drug in the treatment of bipolar depression. Further controlled clinical trials are needed.

Original languageEnglish (US)
Pages (from-to)195-198
Number of pages4
JournalJournal of Clinical Psychiatry
Volume66
Issue number2
DOIs
StatePublished - Jan 1 2005

Fingerprint

zonisamide
Bipolar Disorder
Therapeutics
Controlled Clinical Trials
Diagnostic and Statistical Manual of Mental Disorders
Pharmaceutical Preparations
Analysis of Variance
Observation

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. / Anand, Amit; Bukhari, Lubna; Jennings, Shirley A.; Lee, Cynthia; Kamat, Mamata; Shekhar, Anantha; Nurnberger, John I.; Lightfoot, Jeffrey.

In: Journal of Clinical Psychiatry, Vol. 66, No. 2, 01.01.2005, p. 195-198.

Research output: Contribution to journalArticle

Anand, Amit ; Bukhari, Lubna ; Jennings, Shirley A. ; Lee, Cynthia ; Kamat, Mamata ; Shekhar, Anantha ; Nurnberger, John I. ; Lightfoot, Jeffrey. / A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. In: Journal of Clinical Psychiatry. 2005 ; Vol. 66, No. 2. pp. 195-198.
@article{70547fb890f840f9949f4e9f768da2f8,
title = "A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients",
abstract = "Objective: The purpose of this study was to investigate the effectiveness of zonisamide in the treatment of bipolar depression. Method: Ten patients with DSM-IV bipolar disorder, depressed phase, who had either not tolerated or not responded to previous treatments were given zonisamide in this add-on open-label study. Zonisamide treatment was started at 100 mg/day and increased by 100 mg every 2 weeks to a maximum of 300 mg/day in divided doses (b.i.d. or t.i.d.). Subjects underwent weekly visits at which they were administered the 17-item Hamilton Rating Scale for Depression (HAM-D), Young Mania Rating Scale (YMRS), and Clinical Global Impressions scale (CGI). Every 2 weeks, subjects also underwent laboratory tests, a urine examination, and a verbal memory test. Outcome measures were analyzed with repeated-measures analysis of variance. Results: Eight subjects completed all 8 weeks of the study. Two subjects completed more than 4 weeks of the study, and their data were analyzed using the last observation carried forward. Bipolar depression subjects had a significant reduction in HAM-D scores (p < .001) and in CGI-Improvement (CGI-I) scores (p < .001). Five of 8 subjects who completed all 8 weeks of the study had more than a 50{\%} decrease in HAM-D scores and were rated much improved on the CGI-I at the end of 8 weeks of treatment. There was no significant drug effect on YMRS scores, weight, or verbal memory. Conclusion: Zonisamide may be a useful drug in the treatment of bipolar depression. Further controlled clinical trials are needed.",
author = "Amit Anand and Lubna Bukhari and Jennings, {Shirley A.} and Cynthia Lee and Mamata Kamat and Anantha Shekhar and Nurnberger, {John I.} and Jeffrey Lightfoot",
year = "2005",
month = "1",
day = "1",
doi = "10.4088/JCP.v66n0206",
language = "English (US)",
volume = "66",
pages = "195--198",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "2",

}

TY - JOUR

T1 - A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients

AU - Anand, Amit

AU - Bukhari, Lubna

AU - Jennings, Shirley A.

AU - Lee, Cynthia

AU - Kamat, Mamata

AU - Shekhar, Anantha

AU - Nurnberger, John I.

AU - Lightfoot, Jeffrey

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Objective: The purpose of this study was to investigate the effectiveness of zonisamide in the treatment of bipolar depression. Method: Ten patients with DSM-IV bipolar disorder, depressed phase, who had either not tolerated or not responded to previous treatments were given zonisamide in this add-on open-label study. Zonisamide treatment was started at 100 mg/day and increased by 100 mg every 2 weeks to a maximum of 300 mg/day in divided doses (b.i.d. or t.i.d.). Subjects underwent weekly visits at which they were administered the 17-item Hamilton Rating Scale for Depression (HAM-D), Young Mania Rating Scale (YMRS), and Clinical Global Impressions scale (CGI). Every 2 weeks, subjects also underwent laboratory tests, a urine examination, and a verbal memory test. Outcome measures were analyzed with repeated-measures analysis of variance. Results: Eight subjects completed all 8 weeks of the study. Two subjects completed more than 4 weeks of the study, and their data were analyzed using the last observation carried forward. Bipolar depression subjects had a significant reduction in HAM-D scores (p < .001) and in CGI-Improvement (CGI-I) scores (p < .001). Five of 8 subjects who completed all 8 weeks of the study had more than a 50% decrease in HAM-D scores and were rated much improved on the CGI-I at the end of 8 weeks of treatment. There was no significant drug effect on YMRS scores, weight, or verbal memory. Conclusion: Zonisamide may be a useful drug in the treatment of bipolar depression. Further controlled clinical trials are needed.

AB - Objective: The purpose of this study was to investigate the effectiveness of zonisamide in the treatment of bipolar depression. Method: Ten patients with DSM-IV bipolar disorder, depressed phase, who had either not tolerated or not responded to previous treatments were given zonisamide in this add-on open-label study. Zonisamide treatment was started at 100 mg/day and increased by 100 mg every 2 weeks to a maximum of 300 mg/day in divided doses (b.i.d. or t.i.d.). Subjects underwent weekly visits at which they were administered the 17-item Hamilton Rating Scale for Depression (HAM-D), Young Mania Rating Scale (YMRS), and Clinical Global Impressions scale (CGI). Every 2 weeks, subjects also underwent laboratory tests, a urine examination, and a verbal memory test. Outcome measures were analyzed with repeated-measures analysis of variance. Results: Eight subjects completed all 8 weeks of the study. Two subjects completed more than 4 weeks of the study, and their data were analyzed using the last observation carried forward. Bipolar depression subjects had a significant reduction in HAM-D scores (p < .001) and in CGI-Improvement (CGI-I) scores (p < .001). Five of 8 subjects who completed all 8 weeks of the study had more than a 50% decrease in HAM-D scores and were rated much improved on the CGI-I at the end of 8 weeks of treatment. There was no significant drug effect on YMRS scores, weight, or verbal memory. Conclusion: Zonisamide may be a useful drug in the treatment of bipolar depression. Further controlled clinical trials are needed.

UR - http://www.scopus.com/inward/record.url?scp=14644422141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644422141&partnerID=8YFLogxK

U2 - 10.4088/JCP.v66n0206

DO - 10.4088/JCP.v66n0206

M3 - Article

C2 - 15705004

AN - SCOPUS:14644422141

VL - 66

SP - 195

EP - 198

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 2

ER -